GREY:ICOTF - Post by User
Post by
MountainMasteron Jun 21, 2018 6:22pm
121 Views
Post# 28209287
Yesterdays News
Yesterdays News About iCo Therapeutics Inc.
iCo Therapeutics identifies existing development-stage assets for use in underserved ocular and infectious diseases. Such assets may exhibit utility in non-ophthalmic conditions outside the company's core focus areas, and, if so, the company will seek to capture further value through partnerships, such as its partnership with Immune Pharmaceuticals, which is in several phase 2 studies involving iCo-008.
IMNP / Immune Pharmaceuticals had a nice year high of
$3.43 ICO could easily follow especially with pending news/results on the way. Just an observation but it looks like ICO is going to go a lot higher.